Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543102 | 0.84 | KDR (0.45) | KDRKMT2AMEN1MAPT | |
| SCHEMBL446890 | 0.83 | KDR (0.63) | KDR | |
| SCHEMBL6542940 | 0.83 | CHEK1 (0.50) | KDR | |
| SCHEMBL3119364 | 0.80 | KDR (0.45) | KDRKMT2AMEN1MAPT | |
| SCHEMBL1490923 | 0.79 | KIT (0.51) | KDR | |
| SCHEMBL6542828 | 0.79 | KDR (0.49) | KDRKMT2AMEN1MAPT | |
| SCHEMBL6543388 | 0.78 | KIT (0.48) | KDR | |
| SCHEMBL3119415 | 0.78 | NPC1 (0.54) | KDRKMT2AMEN1POLBNPC1 | |
| SCHEMBL6542861 | 0.77 | KIT (0.49) | KDR | |
| SCHEMBL3106478 | 0.77 | RXFP1 (0.61) | KDRKMT2AMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168948-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-03-31 | — | — | EP | claimed |
| EP-1259487-B1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | claimed |
| US-6624174-B2 | Especially for treating a neoplastic disease, retinopathy or age-related macular degeneration | NOVARTIS AG (CH) | 2003-09-23 | — | — | US | claimed |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2003-02-13 | — | — | US | claimed |
| EP-2168948-B1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-05-07 | — | — | EP | disclosed |
| EP-2168948-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-1259487-B1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | BOLD GUIDO | 2008-04-10 | — | — | US | disclosed |
| US-6624174-B2 | Especially for treating a neoplastic disease, retinopathy or age-related macular degeneration | NOVARTIS AG (CH) | 2003-09-23 | — | — | US | disclosed |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2003-02-13 | — | — | US | disclosed |
| EP-1259487-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001055114-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | VEGFA, FLT1, FLT4 | KDR 4/4885KMT2A 2853/4885MEN1 2272/4885 |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | KDR, ERBB2, FLT1 | KDR 1/4885KMT2A 2155/4885MEN1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.